{"id":536227,"date":"2021-03-31T05:26:01","date_gmt":"2021-03-31T05:26:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=536227"},"modified":"2021-03-31T05:26:01","modified_gmt":"2021-03-31T05:26:01","slug":"diabetic-nephropathy-pipeline-analysis-across-different-stages-of-development-phase-iii-and-phase-ii-different-emerging-trends-and-comparative-analysis-of-pipeline","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/diabetic-nephropathy-pipeline-analysis-across-different-stages-of-development-phase-iii-and-phase-ii-different-emerging-trends-and-comparative-analysis-of-pipeline_536227.html","title":{"rendered":"Diabetic Nephropathy Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1617084703.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Diabetic Nephropathy Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline\" src=\"https:\/\/www.abnewswire.com\/uploads\/1617084703.jpeg\" alt=\"Diabetic Nephropathy Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>&ldquo;<span style=\"text-decoration: underline;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-nephropathy-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Diabetic Nephropathy Pipeline<\/a><\/span>&rdquo; report has been added to DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&#8221; <strong>Diabetic Nephropathy<\/strong> Pipeline Insights, 2021&#8243; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the <strong>Diabetic Nephropathy<\/strong> market. A detailed picture of the <strong>Diabetic Nephropathy<\/strong> pipeline landscape is provided, which includes the disease overview and <strong>Diabetic Nephropathy<\/strong> treatment guidelines. The assessment part of the report embraces in-depth <strong>Diabetic Nephropathy<\/strong> commercial assessment and clinical assessment of the <strong>Diabetic Nephropathy<\/strong> pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, <strong>Diabetic Nephropathy<\/strong> collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download free sample copy- <span style=\"text-decoration: underline;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/diabetic-nephropathy-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/diabetic-nephropathy-pipeline-insight <\/a><\/span><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Geography Covered<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Global<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><span style=\"text-decoration: underline;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-nephropathy-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Diabetic Nephropathy Pipeline Report<\/a><\/span>: Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Diabetic nephropathy is a long-term kidney disease that can affect people with diabetes. It is also known as Diabetic Kidney Disease (DKD). It happens when a person&#8217;s kidneys are damaged by elevated blood glucose levels.&nbsp; Diabetic nephropathy is a leading cause of chronic kidney disease and end-stage renal disease (ESRD). The kidneys in ESRD are no longer able to satisfy the demands of everyday life. Kidney failure can occur as a result of ESRD, which can be life-threatening.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><span style=\"text-decoration: underline;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-nephropathy-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\"><strong>Diabetic Nephropathy Emerging Drugs<\/strong><\/a><\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li>LMB763: Novartis<\/li>\n<li>BI 685509: Boehringer Ingelheim<\/li>\n<li>GLY-230: Glycadia<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Diabetic Nephropathy Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\">The report provides insights into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>All of the companies that are developing therapies for the treatment of Diabetic Nephropathy with aggregate therapies developed by each company for the same.<\/li>\n<li>Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Diabetic Nephropathy treatment.<\/li>\n<li>Diabetic Nephropathy key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li>Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Diabetic Nephropathy market.<\/li>\n<li>The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university web sites and industry-specific third-party sources, etc.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Following is the table of content of Diabetic Nephropathy Pipeline Report<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Diabetic Nephropathy&nbsp;<\/p>\n<p style=\"text-align: justify;\">3. Diabetic Nephropathy&nbsp;Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\">4. Diabetic Nephropathy&nbsp;&#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">6. Diabetic Nephropathy Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\">7. Diabetic Nephropathy Mid Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\">12. Diabetic Nephropathy Discontinued Products<\/p>\n<p style=\"text-align: justify;\">13. Diabetic Nephropathy&nbsp;Product Profiles<\/p>\n<p style=\"text-align: justify;\">14. Diabetic Nephropathy&nbsp;Key Companies<\/p>\n<p style=\"text-align: justify;\">15. Diabetic Nephropathy&nbsp;Key Products<\/p>\n<p style=\"text-align: justify;\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\">17. Diabetic Nephropathy&nbsp;Unmet Needs<\/p>\n<p style=\"text-align: justify;\">18. Diabetic Nephropathy&nbsp;Future Perspectives<\/p>\n<p style=\"text-align: justify;\">19. Diabetic Nephropathy&nbsp;Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Diabetic Nephropathy&nbsp;Pipeline: Key Questions<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>What are the current options for <span style=\"text-decoration: underline;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-nephropathy-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Diabetic Nephropathy treatment<\/a><\/strong><\/span>?<\/li>\n<li>How many companies are developing therapies for the treatment of Diabetic Nephropathy?<\/li>\n<li>What are the principal therapies developed by these companies in the industry?<\/li>\n<li>How many therapies are developed by each company for the treatment of Diabetic Nephropathy?<\/li>\n<li>How many Diabetic Nephropathy emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Diabetic Nephropathy?<\/li>\n<li>Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?<\/li>\n<li>What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Diabetic Nephropathy market?<\/li>\n<li>Which are the dormant and discontinued products and the reasons for the same?<\/li>\n<li>What is the unmet need for current therapies for the treatment of Diabetic Nephropathy?&nbsp;<\/li>\n<li>What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Diabetic Nephropathy therapies?<\/li>\n<li>What are the clinical studies going on for Diabetic Nephropathy and their status?<\/li>\n<li>What are the results of the clinical studies and their safety and efficacy?<\/li>\n<li>What are the key designations that have been granted for the emerging therapies for Diabetic Nephropathy?<\/li>\n<li>How many patents are granted and pending for the emerging therapies for the treatment of Diabetic Nephropathy?<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=diabetic-nephropathy-pipeline-analysis-across-different-stages-of-development-phase-iii-and-phase-ii-different-emerging-trends-and-comparative-analysis-of-pipeline\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=diabetic-nephropathy-pipeline-analysis-across-different-stages-of-development-phase-iii-and-phase-ii-different-emerging-trends-and-comparative-analysis-of-pipeline\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; &ldquo;Diabetic Nephropathy Pipeline&rdquo; report has been added to DelveInsight &nbsp; &#8221; Diabetic Nephropathy Pipeline Insights, 2021&#8243; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Diabetic Nephropathy market. A detailed picture of &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/diabetic-nephropathy-pipeline-analysis-across-different-stages-of-development-phase-iii-and-phase-ii-different-emerging-trends-and-comparative-analysis-of-pipeline_536227.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,423,413],"tags":[],"class_list":["post-536227","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/536227","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=536227"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/536227\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=536227"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=536227"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=536227"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}